CHARGED ALPHATMFrontier AI stock research

ELAN · NYSE

Elanco Animal Health Incorporated

Drug Manufacturers - Specialty & Generic · United States

USD 22.360.2% daily changeQuote 2026-09-28 · USD
Market cap (USD)
US$11.17B
Trailing P/E
—
Forward P/E
17.41x
Quarterly revenue growth
10.2%
Trailing net margin
-4.0%
Indicated dividend yield
—

Snapshot 2026-09-28 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-11-06 (provider estimate, not issuer-confirmed).

Company background

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Company website

Q2 2026

Go beyond the headline.

Elanco (ELAN): A 26% Beat, A Third Straight Raise - And The Stock Fell 17%

Published 2026-08-07

Comparable businesses

ELAN peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricELANElanco Animal Health IncorporatedSnapshot 2026-09-28Financial period: 2026-06-30RDYDr. Reddy's Laboratories LimitedSnapshot 2026-09-28Financial period: 2026-06-30AMRXAmneal Pharmaceuticals, Inc.Snapshot 2026-09-28Financial period: 2026-06-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$11.17BUS$10.45BUS$6.93BUS$8.69Bn=2
Forward P/EProvider forward earnings estimate17.41x19.36x16.70x18.03xn=2
EV / EBITDAEnterprise value / trailing EBITDA14.75x—13.14x—
Revenue growthLatest quarter vs prior-year quarter10.2%-5.6%9.9%2.1%n=2
Operating marginLatest reported quarter8.6%4.3%18.3%11.3%n=2
Free cash flow yieldTrailing cash flow / market cap7.4%—-1.7%—
Net debt / EBITDANet debt / trailing EBITDA3.68x-0.17x3.86x1.84xn=2
Debt / equityTotal debt / positive book equity0.64x0.19x23.87x12.03xn=2
Trailing P/ETrailing twelve-month earnings—30.59x41.48x36.03xn=2
Price / bookPrice / positive book equity per share1.70x15.41x193.30x104.36xn=2
EV / salesEnterprise value / trailing revenue2.96x—2.90x—
Earnings growthLatest quarter vs prior-year quarter440.5%-68.7%157.1%44.2%n=2
Gross marginTrailing twelve months55.4%50.2%39.8%45.0%n=2
Net marginTrailing twelve months-4.0%10.0%5.0%7.5%n=2
Return on equityProvider trailing return; positive equity only-3.0%8.8%613.0%310.9%n=2
Free cash flow marginTrailing free cash flow / revenue16.5%-1.2%-3.7%-2.4%n=2
Dividend yieldIndicated annual dividend / price—0.6%——
Earnings payoutProvider trailing dividend payout0.0%20.2%0.0%10.1%n=2
Current ratioCurrent assets / current liabilities2.05x1.90x2.21x2.05xn=2
BetaProvider historical market sensitivity1.680.241.240.74n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-09-28. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for ELAN

All available reporting periods
Q2 20262026-08-07

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.